Lakefront Biotherapeutics

Unternehmensprofil

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Beschreibung auf Englisch verfügbar.

Unternehmensdaten

Branche

Gesundheit

Industrie

Biotechnology

Land

Niederlande

Hauptsitz

SchaliEnhoevedreef 20 T, 2800, Mechelen

Mitarbeitende

196

Notierung

LKFT · Euronext Amsterdam

Währung

EUR

ISIN

BE0003818359

Website

lakefrontbio.com